Formulations of AG10
AssigneeEidos Therapeutics, Inc.
InventorsJesper Jernelius, Mark Michael Menning
Life of this patent
Estimating the term…
Abstract
The present disclosure provides high-load tablet formulations of AG10 or a pharmaceutically acceptable salt thereof. In some aspects, provided herein are table formulations of AG10 or a pharmaceutically acceptable salt thereof that include at least 40% or more AG10 by weight and at least one pharmaceutical excipient selected from one or more fillers, one or more binders, one or more disintegrants, and one or more lubricants.
Claims26
A tablet formulation comprising AG10 or a pharmaceutically acceptable salt thereof and one or more fillers, one or more disintegrants, and one or more lubricants, wherein
- said tablet formulation comprises:
- 40 to 85% by weight of AG10 or a pharmaceutically acceptable salt thereof;
- 5 to 55% by weight of said one or more fillers;
- 3 to 8% by weight of said one or more disintegrants;
- and
- 0.5 to 3% by weight of said one or more lubricants, and wherein said one or more fillers comprise a high-grade microcrystalline cellulose characterized by cellulose polymers with (i) spherical morphology and porous structure or (ii) needle-like particle shape.
A tablet formulation comprising AG10 or a pharmaceutically acceptable salt thereof and one or more fillers, one or more disintegrants, and one or more lubricants, wherein
- said tablet formulation comprises:
- 50 to 75% by weight of AG10 or a pharmaceutically acceptable salt thereof;
- 15 to 45% by weight of said one or more fillers;
- 3 to 8% by weight of said one or more disintegrants;
- and
- 0.5 to 3% by weight of said one or more lubricants, and
- wherein said one or more fillers comprise a high-grade microcrystalline cellulose characterized by cellulose polymers with (i) spherical morphology and porous structure or (ii) needle-like particle shape.
Dependencies are inferred from the claim text.